Press Releases

LAKEWOOD, Colo., June 11, 2026 /PRNewswire/ -- Natural Grocers®, the leading family-operated organic and natural grocery retailer in the U.S., invites customers to its annual New Mexico Day event, June 14 through June 16 at its seven New Mexico stores. {N}power® members are invited to celebrate with a free Natural Grocers reusable tote bag and a $5-off coupon for in-store purchases. NATURAL GROCERS – NEW MEXICOHeadquartered in Colorado, Natural Grocers expanded into New Mexico in 2003. Today Natural Grocers operates seven stores in the Land of Enchantment, including Albuquerque, Farmington, Las Cruces, Los Alamos, Rio Rancho, R

--Revenue increases 8% to $484 million with same store sales growth of 2%-- --Take 5 same store sales increase 4.5%; 23rd consecutive quarter of growth-- --Net leverage ratio improves to 3.2x Adjusted EBITDA-- --Company reiterates fiscal year 2026 outlook-- Driven Brands Holdings Inc. (NASDAQ:DRVN) ("Driven Brands" or the "Company") today reported financial results for the first quarter ending March 28, 2026. For the first quarter, Driven Brands delivered revenue of $484.4 million, an increase of 8% versus the prior year. System-wide sales increased 6% to $1.6 billion, driven by a 2% increase in same store sales and 5% increase in store count versus the prior year. Net income fr

TORONTO, June 11, 2026 /PRNewswire/ -- Thomson Reuters (TSX/Nasdaq: TRI) today announced the voting results for the election of the company's Board of Directors at its annual meeting of shareholders held in-person yesterday. All 14 nominees were elected to the Thomson Reuters Board of Directors. Michael Medline and Liz Hilton Segel are newly elected directors. Each director elected will continue to hold office until Thomson Reuters' next annual meeting of shareholders, or until the director resigns or a successor is elected or appointed. The voting results for directors were as follows:Nominee     Votes For             % Votes 

Coursera, Inc. (NYSE:COUR), a leading global online learning platform, today announced that it will host a supplemental post-merger modeling call on Tuesday, June 23, 2026, at 5:30 a.m. PT / 8:30 a.m. ET. The company's chief financial officer, Mike Foley, will provide an overview of the combined company's full year 2026 financial profile following the close of its merger with Udemy on May 11, 2026. Prepared remarks will be followed by an analyst question-and-answer session.A live webcast and archived replay of the virtual conversation will be available on Coursera's investor relations website at investor.coursera.com.Disclosure InformationIn compliance with disclosure obligations under Regul

NASDAQ | TSX: ACBAchieves Record Annual Global Medical Cannabis Net Revenue1 of $288.6 million, representing 18% YoY growthDelivers Record Annual Adjusted EBITDA1 of $53.8 million, representing 32% YoY growthCompletes Accretive Acquisition of Safari Flower Company in April, an established EU-GMP Manufacturer, adding Critical Capacity to Serve Growing Profitable International MarketsMaintains Strong Balance Sheet with ~$164.7 million of Cash, Short Term Investments and Cash Equivalents2 with no DebtEDMONTON, AB, June 11, 2026 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced its financial an

Experienced Biotech Leader with More than Two Decades of Experience Advancing Therapies from Discovery through Regulatory Approval SAN DIEGO, June 11, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the appointment of Hubert C. Chen, M.D., as chief medical officer.  Dr. Chen brings more than two decades of leadership experience in senior executive roles spanning drug discovery, clinical development, regulatory strategy, and product approvals across multiple therapeutic areas.  Dr. Chen will report to Brian Lian, Ph.D., presiden

HOLON, Israel, June 11, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery powered by AI/ML, today announced that it will present a trial-in-progress poster on the MAIA-ovarian Phase 1 study of COM701, a potential first-in-class anti-PVRIG antibody, at the ESMO Gynaecological Cancers Congress 2026, taking place from June 17 to June 19, 2026, in Copenhagen, Denmark. Poster details: Title: MAIA-ovarian (NCT06888921) Adaptive Platform Clinical Trial to Evaluate Safety and Efficacy of COM701 Maintenance Treatment in Relapsed Platinum Sensitive Ovarian Cancer (PSOC)Speaker: Dr.

– Real-world study of revumenib shows 82% (9/11) ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or KMT2Ar patients treated with revumenib monotherapy or combinations – – Ph 1 trial of revumenib with intensive chemotherapy in newly diagnosed NPM1m or KMT2Ar AML shows 97% (34/35) CRc and 86% (25/29) MRD negativity among CRc responders – – Post-hoc analysis of patients with R/R NPM1m, KMT2Ar, or NUP98r acute leukemia in the AUGMENT-101 trial who resumed revumenib post-HSCT shows an observed 1-year OS of 95% – – Phase 1 trial and expanded access experience shows 28% (7/25) ORR in R/R NUP98r acute leukemia, a subtype with a poor prognosis and high unmet need – – Ph 2 SAVE trial of revumenib w

Uklon Store, Uklon's first move into everyday commerce, opens with flower deliveries in Kyiv. Customers can buy a bouquet in a few taps and have it delivered the same day by Uklon drivers. Dubai, Kyiv, and New York, June 11, 2026 – VEON Ltd. (NASDAQ:VEON), a global digital operator and the parent company of Kyivstar Group Ltd. (NASDAQ:KYIV, KYIVW)), today announced that Uklon, the ride-hailing service used by millions of Ukrainians every day, has opened Uklon Store, the company's first step beyond mobility, travel and logistics into in-app commerce. Uklon Store is a new way to buy goods and have them delivered from right inside the Uklon app. The first items customers can order are flowers,

TORONTO, June 11, 2026 /PRNewswire/ - A2Z Cust2Mate Solutions Corp. (NASDAQ:AZ), a global leader in smart retail technology, today announced that its mass production facilities in China are fully operational, with large-scale manufacturing now underway. The launch of full-scale manufacturing marks a significant milestone in the Company's growth strategy, providing the production capacity needed to support increasing demand from retailers across multiple markets. With manufacturing operations now running at scale, Cust2Mate has begun shipping systems to support both existing and new deployments.To have a firsthand look at the Company's production facilities being inaugurated by A2Z Cust2Mate

TORONTO, June 11, 2026 /CNW/ - IsoEnergy Ltd. ("IsoEnergy", or the "Company") (NYSE:ISOU) (TSX:ISO) is pleased to announce the commencement of its 2026 summer exploration program on the Larocque East project (the "Project"), which hosts the high-grade Hurricane deposit ("Hurricane" or the "Deposit"), in the eastern Athabasca Basin, Canada. The program is planned to comprise approximately 8,000 m of diamond drilling across up to 20 drill holes, focused on following up high-grade winter 2026 results (see press release dated May 12, 2026) along the highly prospective Hurricane South Trend (Figure 1).Hurricane hosts a current Mineral Resource of 48.6 Mlb U3O8 at 34.5% U3O8 Indicated, and 2.7 Mlb

Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib Safety profile was consistent with previous studies with no new safety signals identified Takeda ((TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with

Eliminates approximately $23 million of debt, resulting in approximately $2 million in annual interest savings Principal to be paid in cash, remainder in common stock Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into separate, privately negotiated exchange agreements with certain holders of its 8.00% Convertible Senior Notes due 2028 (the "Notes"). Pursuant to the exchange agreements, Xeris has agreed, subject to customary closing conditions, to retire approximately $23 million aggregate princi

Super Micro Computer, Inc. (NASDAQ:SMCI) ("Supermicro" or the "Company"), a Total IT Solution Manufacturer for AI, Cloud, Storage, and 5G/Edge, today announced the pricing of its previously announced series of concurrent equity and equity-linked financing transactions. The gross proceeds of these offerings, together with potential gross proceeds of Supermicro's $1.25 billion at-the-market, or ATM, offering program for the sale of common stock over time, represent a total potential equity raise of $7.0 billion, inclusive of the underwriters' options to purchase additional shares and additional depositary shares for the common stock offering and the depositary shares offering, respectively.

SS&C GlobeOp Hedge Fund Performance Index: May performance 1.77% SS&C GlobeOp Capital Movement Index: June net flows advance 0.75% SS&C Technologies Holdings, Inc. (NASDAQ:SSNC) today announced the gross return of the SS&C GlobeOp Hedge Fund Performance Index for May 2026 measured 1.77%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611372432/en/SS&C GlobeOp Hedge Fund Performance Index Hedge fund flows as measured by the SS&C GlobeOp Capital Movement Index advanced 0.75% in June. "Hedge funds benefited from another strong month of inflows in June 2026, with SS&C GlobeOp's Capital Movement Index advancing 0.75%," said Bi

The weight loss and weight management market was valued at $31.07 billion in 2025 A program can describe its results as clinically meaningful without specifying what was measured, how it was measured, or whether the measurement tool was capable of capturing the outcome being claimedDXA scanning distinguishes fat mass, lean mass, and bone mineral content with greater precision than BMI calculations and just weight number on a scaleStudy completion rates carry significant weight in how research findings should be interpreted BALTIMORE, MD, June 11, 2026 (GLOBE NEWSWIRE) -- Subscription health programs compete on outcome language as much as they compete on results. Terms like "clinically st

– High response rates observed with the all-oral combination in a heavily pretreated population, including 88% (37/42) ORR, 71% (30/42) CRc, and 60% CR/CRh (25/42) – – Strong activity across subgroups, including 70% (14/20) CR/CRh in venetoclax-naïve and 50% (11/22) CR/CRh in venetoclax-exposed patients – – Deep responses with 80% (24/30) MRD negativity among evaluable CRc responders – – Robust transplant rate with 45% (19/42) of patients proceeding to transplant and 63% (12/19) resuming revumenib post-transplant – – Encouraging durability with median overall survival after transplant not reached –  – Combination was generally well-tolerated – NEW YORK, June 11, 2026 (GLOBE NEWSWIRE)

Declining estrogen during perimenopause accelerates visceral fat accumulation and lean muscle loss, two outcomes that standard weight management programs are not designed to address together (Szeliga A, et al., 2026)Women in midlife who focus on scale weight alone may be measuring the wrong thing: visceral fat and lean mass retention are the markers that reflect metabolic progressSleep disruption, elevated stress, and hormonal variability during midlife create conditions where self-directed programs stallThe coaching gap in weight loss outcomes becomes more significant during hormonal transition, when behavioral disruptions make self-directed programs harder to sustain BALTIMORE, MD, June

High objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor and have not received BCL2 inhibitor treatment Updated Phase 1a data further supports a median progression-free survival of 22.1 months and an objective response rate of 83% in heavily pretreated relapsed/refractory CLL/SLL patients Bexobrutideg was well tolerated with longer follow-up demonstrating a safety profile consistent with prior disclosures Responses observed across difficult-to-treat patient subgroups, including high-risk features, BTK resistance mutations and CNS involvement Data to be presented at the 2026 European Hematology Association (EHA) Congress BRISBANE, Calif., June

Data demonstrate favorable safety and tolerability profile, robust B-cell depletion, and encouraging platelet responses in heavily pretreated patients with primary immune thrombocytopenia Enrollment ongoing in the high dose cohort, with additional data anticipated by year-end 2026 WELLESLEY HILLS, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced initial data from the ongoing Phase 1b portion of its Phase 1b/2a study evaluating budoprutug, an anti-CD19 monoclonal antibody, in adults with primary immune thrombocytopenia (ITP) demonstrating an enc